Along with the detrimental effects on muscle function, we observed a rise in gastrointestinal incretins (GIP and GLP-1), C-peptide, and glucagon levels, along with low PAI-1 levels, in breast cancer patients, independently. Here, GIP is linked to breast carcinoma.